Sorrento Therapeutics (SRNE) 10.55 $SRNE
Oxford Finance and Silicon Valley Bank Expand Existing Senior Credit Facility with Sorrento Therapeutics to $12.5 Million
PR Newswire - Wed Apr 16, 9:00AM CDT
Oxford Finance LLC ("Oxford"
, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, and Silicon Valley Bank, today announced a $7.5 million expansion to an existing $5 million term loan with Sorrento Therapeutics, Inc ("Sorrento" . Proceeds of the loan will be used to advance the development of multiple programs and platforms.
Sorrento Therapeutics (SRNE) in Focus: Stock Tumbles 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:41AM CDT
Sorrento Therapeutics (SRNE) fell over 16% in the last trading session amid huge volumes, continuing its recent downtrend as the stock is now down over 45% since March 21.
Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development
PR Newswire - Mon Apr 07, 2:58PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of Ian B. Walters, M.D., MBA., a translational oncology and immunology expert. Dr. Walters was most recently an executive at Bristol Myers Squibb (BMS) where he led oncology drug development programs, large international matrix teams, and strategic transactions. He has more than 15 years of entrepreneurial drug development and business experience in both small biotechnology and big pharmaceutical companies.
Sorrento Therapeutics Announces Key Presentation on Cynviloq at the American Association for Cancer Research Annual Meeting
PR Newswire - Fri Apr 04, 8:43AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies.
Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting
PR Newswire - Fri Apr 04, 5:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of resiniferatoxin (RTX) for the treatment of intractable cancer pain. The data were presented at the 39th Annual Regional Anesthesia and Acute Pain Meeting, organized by the American Society of Regional Anesthesia and Pain Medicine (ASRA), in Chicago on April 3, 2014.
Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane
PR Newswire - Mon Mar 31, 8:31PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer.
Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications
PR Newswire - Tue Mar 25, 6:47AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the formation of a wholly-owned subsidiary, Ark Animal Therapeutics, initially devoted to developing resiniferatoxin (RTX) for multiple veterinary health applications and vaccines against recurrent staphylococcal infections.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
PR Newswire - Tue Mar 11, 5:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran Mark W. Durand to its Board of Directors.
Sorrento Therapeutics (SRNE) Soars: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:39AM CST
Sorrento Therapeutics, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Sorrento Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference
PR Newswire - Thu Mar 06, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the ROTH Capital Partners 26th Annual Growth Stock Conference. The presentation will take place at noon PDT on Tuesday, March 11, in Salon 5 of the Ritz Carlton in Dana Point, Calif.
Sorrento Therapeutics Announces Three Presentations and a Satellite Symposium on Cynviloq(TM) at the 31st Annual Miami Breast Cancer Conference
PR Newswire - Thu Mar 06, 4:50AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present a comparison of the pharmacokinetic (PK) properties of Cynviloq and nab-paclitaxel (Abraxane®) at the 31st Annual Miami Breast Cancer Conference in Miami Beach, Florida. Highlights of the findings include new and historical data on PK bioequivalence of Cynviloq and nab-paclitaxel in mouse, dog, and monkey, as well as an analysis of PK characteristics in humans based on published data. Phase 4 data for Cynviloq from South Korea will also be discussed.
Sorrento Therapeutics names Dr Mike Royal as SVP of Clinical Development
M2 - Mon Mar 03, 6:33AM CST
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the appointment of Dr Mike Royal, MD, JD and MBA, as senior vice president of its Clinical Development.
Sorrento Therapeutics hires Mike Royal as Senior Vice President of Clinical Development
PR Newswire - Mon Mar 03, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of anesthesiologist and pain specialist, Mike Royal, M.D., JD and MBA. He was most recently Chief of Clinical Affairs at AcelRx.
Sorrento (SRNE) Jumps: Stock Adds 11.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:46AM CST
Sorrento Therapeutics was a big mover last session, with shares rising just over 11%.
Sorrento Therapeutics Announces Two Presentations on Cynviloq(TM) at the Beaujon International Conference on "Cutting Edge in Liver and Pancreatic Tumors"
PR Newswire - Tue Feb 11, 7:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that it will present results of preclinical and Phase II clinical studies of Cynviloq(TM) in patients with metastatic pancreatic cancer at the Beaujon International Conference: Cutting Edge in Liver and Pancreatic Tumors in Paris, France on February 13, 2014. Highlights of the findings include data on Cynviloq Phase II monotherapy and Phase I combination therapy with Gemcitabine that support similar efficacy of Cynviloq when compared to historical data for nab-paclitaxel (Abraxane®).
Sorrento Therapeutics Inc acquires the exclusive rights to Cynviloq to expand into Australia, Canada and Mexico
M2 - Tue Feb 11, 6:32AM CST
Oncology company Sorrento Therapeutics Inc (NASDAQ:SRNE) said on Monday that it has acquired the exclusive rights to Cynviloq in Australia, Canada and Mexico from Samyang Biopharmaceuticals, a South Korean corporation.
Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq(TM) to Include Australia, Canada and Mexico
PR Newswire - Mon Feb 10, 3:00PM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today the Company has obtained exclusive rights to Cynviloq(TM) (marketed as Genexol-PM® in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals ("Samyang" , a South Korean corporation. Sorrento already has exclusive rights from Samyang for Cynviloq in the U.S. and the 27 countries of the European Union.
Sorrento Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
PR Newswire - Thu Feb 06, 7:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10 -11 at the Waldorf Astoria in New York City.
Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board
PR Newswire - Mon Feb 03, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation.
Oxford Finance and Silicon Valley Bank Expand Existing Senior Credit Facility with Sorrento Therapeutics to $12.5 Million
PR Newswire - Wed Apr 16, 9:00AM CDT
Oxford Finance LLC ("Oxford"
, a specialty finance firm that provides senior debt to life sciences and healthcare services companies, and Silicon Valley Bank, today announced a $7.5 million expansion to an existing $5 million term loan with Sorrento Therapeutics, Inc ("Sorrento" . Proceeds of the loan will be used to advance the development of multiple programs and platforms. Sorrento Therapeutics (SRNE) in Focus: Stock Tumbles 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:41AM CDT
Sorrento Therapeutics (SRNE) fell over 16% in the last trading session amid huge volumes, continuing its recent downtrend as the stock is now down over 45% since March 21.
Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development
PR Newswire - Mon Apr 07, 2:58PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of Ian B. Walters, M.D., MBA., a translational oncology and immunology expert. Dr. Walters was most recently an executive at Bristol Myers Squibb (BMS) where he led oncology drug development programs, large international matrix teams, and strategic transactions. He has more than 15 years of entrepreneurial drug development and business experience in both small biotechnology and big pharmaceutical companies.
Sorrento Therapeutics Announces Key Presentation on Cynviloq at the American Association for Cancer Research Annual Meeting
PR Newswire - Fri Apr 04, 8:43AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies.
Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting
PR Newswire - Fri Apr 04, 5:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of resiniferatoxin (RTX) for the treatment of intractable cancer pain. The data were presented at the 39th Annual Regional Anesthesia and Acute Pain Meeting, organized by the American Society of Regional Anesthesia and Pain Medicine (ASRA), in Chicago on April 3, 2014.
Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane
PR Newswire - Mon Mar 31, 8:31PM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer.
Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications
PR Newswire - Tue Mar 25, 6:47AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the formation of a wholly-owned subsidiary, Ark Animal Therapeutics, initially devoted to developing resiniferatoxin (RTX) for multiple veterinary health applications and vaccines against recurrent staphylococcal infections.
Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors
M2 - Fri Mar 14, 4:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vvnwqx/competitor) has announced the addition of the "Competitor Analysis: EGF-R Antibodies - Biosimilars and Biosuperiors" report to their offering. The present Competitive Intelligence Report about EGF-R Antibodies -Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted combined 2013 sales of US$ 2,486 mln. A third EGF-R antibody is approved in a number of less regulated markets. Among the approved indications for use of EGF-R antibodies are K-Ras mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). Further indications are under clinical evaluation. The attractive market size and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered 1. EGF-R Antibodies -Biosimilars and Biosuperiors Marketed EGF-R Antibodies - Erbitux Sales & Pipeline - Vectibix Sales & Pipeline - Nimotuzumab Pipeline EGF-R Antibody Biobetters/Biosuperiors - Engineered EGF-R Antibodies - Bi- and Multispecific EGF-R Antibodies - EGF-R Antibody-Drug Conjugates EGF-R Antibody Biosimilars - Cetuximab Biosimilars - Panitumumab Biosimilars 2. Corporate EGF-R Antibody Biosimilar & Biobetter Pipelines Companies Mentioned - AbbVie - Actavis - Amgen - Avesthagen Pharma - Biocon - BioXpress - Bristol-Myers Squibb (BMS) - Celltrion - Centro de Imunologica Molecular AB (CIMAB) - CytomX Therapeutics - Daiichi Sankyo - Eli Lilly - Fusion Therapeutics - Glycotope - Green Cross - Hospira - Immune Pharmaceuticals - Immunogen - Innogene Kalbiotech - InnoMab - ISU Abxis - Janssen Pharmaceuticals - Med Discover - Merck GKaA - Merrimack Pharmaceuticals - Merus - Oncobiologics - Oncoscience - Pfizer 4 - PharmaPraxis - PlantForm - Roche - Shanghai Zhangjiang Biotechnology - Sorrento Therapeutics - Symphogen - Takeda Pharmaceutical - Viropro - Zyngenia For more information visit http://www.researchandmarkets.com/research/vvnwqx/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
PR Newswire - Tue Mar 11, 5:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of industry veteran Mark W. Durand to its Board of Directors.
Sorrento Therapeutics (SRNE) Soars: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:39AM CST
Sorrento Therapeutics, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Sorrento Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference
PR Newswire - Thu Mar 06, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the ROTH Capital Partners 26th Annual Growth Stock Conference. The presentation will take place at noon PDT on Tuesday, March 11, in Salon 5 of the Ritz Carlton in Dana Point, Calif.
Sorrento Therapeutics Announces Three Presentations and a Satellite Symposium on Cynviloq(TM) at the 31st Annual Miami Breast Cancer Conference
PR Newswire - Thu Mar 06, 4:50AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present a comparison of the pharmacokinetic (PK) properties of Cynviloq and nab-paclitaxel (Abraxane®) at the 31st Annual Miami Breast Cancer Conference in Miami Beach, Florida. Highlights of the findings include new and historical data on PK bioequivalence of Cynviloq and nab-paclitaxel in mouse, dog, and monkey, as well as an analysis of PK characteristics in humans based on published data. Phase 4 data for Cynviloq from South Korea will also be discussed.
Sorrento Therapeutics names Dr Mike Royal as SVP of Clinical Development
M2 - Mon Mar 03, 6:33AM CST
Oncology company Sorrento Therapeutics (NASDAQ:SRNE) reported on Monday the appointment of Dr Mike Royal, MD, JD and MBA, as senior vice president of its Clinical Development.
Sorrento Therapeutics hires Mike Royal as Senior Vice President of Clinical Development
PR Newswire - Mon Mar 03, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of anesthesiologist and pain specialist, Mike Royal, M.D., JD and MBA. He was most recently Chief of Clinical Affairs at AcelRx.
Sorrento (SRNE) Jumps: Stock Adds 11.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:46AM CST
Sorrento Therapeutics was a big mover last session, with shares rising just over 11%.
Sorrento Therapeutics Announces Two Presentations on Cynviloq(TM) at the Beaujon International Conference on "Cutting Edge in Liver and Pancreatic Tumors"
PR Newswire - Tue Feb 11, 7:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that it will present results of preclinical and Phase II clinical studies of Cynviloq(TM) in patients with metastatic pancreatic cancer at the Beaujon International Conference: Cutting Edge in Liver and Pancreatic Tumors in Paris, France on February 13, 2014. Highlights of the findings include data on Cynviloq Phase II monotherapy and Phase I combination therapy with Gemcitabine that support similar efficacy of Cynviloq when compared to historical data for nab-paclitaxel (Abraxane®).
Sorrento Therapeutics Inc acquires the exclusive rights to Cynviloq to expand into Australia, Canada and Mexico
M2 - Tue Feb 11, 6:32AM CST
Oncology company Sorrento Therapeutics Inc (NASDAQ:SRNE) said on Monday that it has acquired the exclusive rights to Cynviloq in Australia, Canada and Mexico from Samyang Biopharmaceuticals, a South Korean corporation.
Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq(TM) to Include Australia, Canada and Mexico
PR Newswire - Mon Feb 10, 3:00PM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today the Company has obtained exclusive rights to Cynviloq(TM) (marketed as Genexol-PM® in South Korea and other countries) in Australia, Canada and Mexico from Samyang Biopharmaceuticals ("Samyang"
, a South Korean corporation. Sorrento already has exclusive rights from Samyang for Cynviloq in the U.S. and the 27 countries of the European Union. Sorrento Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
PR Newswire - Thu Feb 06, 7:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that Dr. Henry Ji, President and Chief Executive Officer of Sorrento, will present at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10 -11 at the Waldorf Astoria in New York City.
Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board
PR Newswire - Mon Feb 03, 5:00AM CST
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the addition of Clinical Oncologist Daniel Levitt, M.D., Ph.D., as a member to its Board of Directors. He currently serves as Executive Vice President and Chief Medical Officer of CytRx Corporation.
